MedTrace Logo

Implication of CD35, CD21 and CD55 in Exudative Age-related Macular Degeneration

NCT01174407 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2010-08-03

No results posted yet for this study

Summary

The purpose of this study is to determine a possible implication of CD21, CD35 and CD55 in the pathogenesis of age-related macular degeneration. The aim is to asses a difference in expression rates of these factors on AMD-patients and a healthy control group.

Conditions

  • Age-Related Macular Degeneration

Interventions

OTHER

cd 35, cd21, cd55

Blood drawing/ 10ml/ once- duration of 1 day of full examination of the patient

Sponsors & Collaborators

  • Rudolf Foundation Clinic

    lead OTHER

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2009-12-31
Completion
2010-08-31

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01174407 on ClinicalTrials.gov